Vosoritide is a biologic therapy approved for the treatment of achondroplasia, the most common form of dwarfism. It is an analog of C-type natriuretic peptide (CNP) that promotes bone growth by inhibiting the FGFR3 signaling pathway, which is overactive in achondroplasia. Administered daily, it has been shown to increase growth velocity in children with the condition. Vosoritide represents a targeted, disease-modifying approach for skeletal dysplasias.
Cleanchem is a trusted provider of premium pharmaceutical reference materials, specializing in Vosoritide and its associated compounds. Our catalog includes pharmacopeial and non-pharmacopeial Vosoritide impurities, metabolites, nitrosamine derivatives (N-NO compounds), and stable isotope-labeled products. These reference standards play a critical role in pharmaceutical R&D, supporting activities such as product formulation, ANDA and DMF submissions, quality assurance, analytical method development, and stability assessments.
All Vosoritide-related substances undergo comprehensive characterization and are delivered with complete Certificates of Analysis and supporting analytical documentation to ensure regulatory adherence. Upon request, we can offer EP/USP traceable standards. Our products are routinely re-evaluated to maintain consistent quality and performance.
English
Arabic
Chinese (Simplified)
French
Japanese
Portuguese
Russian
Spanish
